Perspective

is everything

Spherix delivers the speed, context, and confidence behind better business decisions through AI-accelerated, subject matter expert-validated insights – built on independent, proprietary data from our Stakeholder Community and continuously refreshed.

19/20

of the top pharma & biotech firms trust Spherix

Insight integrity. Accelerated by AI.

Across the pharmaceutical lifecycle, the best decisions are built on a complete understanding of the market.

Yet too often, organizations rely on a single stakeholder perspective to guide strategy. Physician prescribing behavior, patient experience, and payer access decisions are distinct, interconnected forces that rarely tell the same story.

Behind every insight is more than a decade of proprietary primary data, curated respondent communities, and deep therapeutic expertise. AI puts all of it to work faster – surfacing trend shifts and segment differences in hours, not weeks, and helping qualify and connect the right physicians and APPs, patients, and payers to every study. What AI does not do is replace the specialist advising you: every insight is still interpreted, challenged, and validated by people who know your market, through an ongoing advisory relationship, not a one-time transaction.

Why Spherix?

Therapeutic depth

Deep therapeutic expertise starts with specialists who are dedicated to these markets. Backed by more than 10 years of proprietary Spherix data and AI-enhanced analysis, every insight is grounded in long-term market understanding – not a single point in time.

Advisory partnership

Spherix is built around advisory based on independent research. Every client has direct access to the Spherix team members who lead the research, providing working sessions, strategic discussions, and real-world interpretation. AI helps deliver answers faster, but the value comes from the experts behind every recommendation.

Communities built and currated internally

Our proprietary research communities are recruited, screened, and managed by Spherix, giving us direct access to qualified healthcare stakeholders. AI enhances respondent qualification and data quality, helping ensure every study starts with the right voices.

Judgment you can act on

Every insight is developed, validated, challenged, and interpreted by a Spherix specialist before it reaches you. AI accelerates the process, but expert judgment drives every recommendation. That is why 19 of the world's top 20 pharmaceutical and biotech companies trust Spherix as an advisory partner – not simply a source of data.

Three perspectives.
One cohesive story.

Commercial success depends on three decisions that rarely align: what a physician or APP will prescribe, what a patient will accept, and what a payer will cover. The brand that wins has insight into all three.

Spherix offers three dedicated insights pillars, each powered by an independently curated community:

Physician
Patient
Payer (Market Access)

Physician

Understand what is actually driving treatment decisions. Quarterly trending, launch tracking, and chart audits, from a vetted community of practicing physicians and APPs.

Physician Insight →

Patient

Hear the voice of the patient. Spherix patient focused research captures disease experience, treatment satisfaction, and unmet needs

Patient Insight →

Payer

Anticipate access decisions that shape product success. Spherix captures proprietary commercial, government, integrated delivery networks (IDNs), and specialty pharmacy intelligence from key formulary decision makers

Payer Insight →

Think beyond your brand

Spherix uncovers why physicians and APPs prescribe the way they do. This allows you to go deeper than commercial data and trends.

A complete view of the landscape leads to more strategic decision-making – giving your brand and commercial leaders a genuine competitive edge.

Spherix fills in what is missing:

01

The gap between what prescribers say they do and what the prescribing data shows

02

Patient acceptance and persistence patterns your claims data cannot explain

03

Access barriers and reimbursement drivers before they become commercial problems

04

Competitive threats and market shifts your current sources are not capturing

Specialty markets we cover

Across eight therapeutic franchises and a dedicated Market Access practice, our specialists work exclusively in their markets – tracking the dynamics that matter before your team needs to act on them.

Trusted Industry Resource

The difference is our people. Subject matter experts with deep therapeutic experience interpret every finding, drawing on proprietary primary data collected from curated physician, patient, and payer communities. The result is an ongoing advisory partnership—not simply a report.

“Spherix is unparalleled in their timely and accurate market snapshots with comprehensive feedback on physicians' impressions, use patterns and projected use of key drugs across the therapeutic categories covered. They are my go-to source when I want insights as to how to model a launch, a competitive dynamic or understand awareness around pipeline agents.”

"Spherix offerings have provided us with an external source of reference which, when compared with our custom market research, led us to include a potentially lucrative segment of physicians in our target list leading to increased growth.”

"We incorporated Spherix’s insights into materials shared with two separate parties conducting diligence on our lead asset. Their work helped us clearly demonstrate the persistent unmet need in our lead indication, reinforcing the strength of our data with an independent, external perspective. The analysis added credibility and supported our conclusion that this therapeutic area continues to present significant opportunity."

"In discussions with a potential partner exploring opportunities beyond our lead indication, Spherix’s analysis proved invaluable. Spherix’s comprehensive comparison of unmet needs across multiple conditions offered a uniquely credible and consistent dataset—something that’s rarely available when drawing from disparate sources. This foundation enabled a more robust and objective dialogue around the relative attractiveness and development potential of several key indications, ultimately helping us and our partner align on strategic priorities."

“Spherix's Dynamix studies provide us invaluable insights into the physician-patient exchange that guides both our patient-facing programs and our interactions with pharma partners. Their survey reports highlight needs that cannot be assessed by EMR data alone. They also reveal information and resources that patients are not receiving, gaps in support that we can fill. These reports are a glimpse into the patient exam room that we can't get anywhere else.”

Latest news and insights from Spherix.

Gastroenterology • Press Release

Exciting Advances in Ulcerative Colitis Treatments: Skyrizi Gains Early Momentum Following FDA Approval in June

August 16, 2026

Dermatology • Press Release

Long-Term Psoriatic Arthritis Data for AbbVie’s Skyrizi Likely to Impact Future IL-23 Preference, Spherix Global Insights Reports

August 16, 2026

Gastroenterology • Media Coverage

The Oral GLP-1 Tracker: Novo’s oral Wegovy hits 3M prescription milestone as Lilly’s Foundayo chugs along in early launch

August 16, 2026

Gastroenterology • Press Release

Spherix Global Insights Reports Persistent High Unmet Need in Europe’s Evolving MASH Market

July 8, 2026

Talk to an expert

Every specialty area at Spherix is led by a highly-experienced insights leader who works exclusively in that market and are always a call or email away.

Sarah Hendry

Hematology & Oncology

Jim Hickey

Gastroenterology

Kari McCarthy

Nephrology

Sybil Mead

Market Access

Lynn Price